enVVeno Medical financials
$8.63−2.10%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$3.8M | -$4.1M | -$4.0M | -$4.9M | -$7.0M | -$5.0M | -$6.7M | -$6.2M | -$5.5M | -$5.5M | -$6.3M | -$5.3M |
| Net income | -$3.6M | -$3.8M | -$3.7M | -$4.5M | -$6.7M | -$4.5M | -$6.2M | -$5.6M | -$5.0M | -$5.0M | -$5.6M | -$5.0M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-5.37 | $-5.89 | — | $-8.05 | $-11.52 | $-7.75 | $-10.70 | $-12.25 | $-10.85 | $-10.85 | $-12.75 | $-15.75 |
| EBITDA | -$3.9M | -$4.0M | -$4.0M | -$4.9M | -$7.0M | -$4.9M | -$6.7M | -$6.1M | -$5.4M | -$5.4M | -$6.2M | -$5.3M |
| Operating cash flow | -$3.5M | -$3.2M | -$3.4M | -$4.4M | -$3.7M | -$4.0M | -$5.1M | -$4.3M | -$3.9M | -$3.5M | -$5.0M | -$4.2M |
| Free cash flow | -$3.5M | -$3.2M | -$3.4M | -$4.4M | -$3.7M | -$4.0M | -$5.1M | -$4.3M | -$3.9M | -$3.6M | -$5.0M | -$4.2M |
| Diluted shares | 0.7M | 0.7M | — | 0.6M | 0.6M | 0.6M | 0.6M | 0.5M | 0.5M | 0.5M | 0.4M | 0.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.8M | $2.6M | $3.1M | $1.5M | $2.0M | $2.9M |
| Short-term investments | $18.6M | $22.3M | $25.1M | $29.4M | $33.1M | $36.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $22.7M | $26.1M | $29.6M | $32.4M | $36.6M | $40.6M |
| Total liabilities | $2.0M | $2.4M | $2.4M | $2.9M | $3.5M | $2.3M |
| Shareholders' equity | $20.7M | $23.7M | $27.1M | $29.4M | $33.1M | $38.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology